menu
    • menu
    [{"orgOrder":0,"company":"IntelGenx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Montelukast Sodium","moa":"CysLT1","graph1":"Neurology","graph2":"Phase II","graph3":"IntelGenx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"buccal film","sponsorNew":"IntelGenx \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"IntelGenx \/ Not Applicable"},{"orgOrder":0,"company":"Novateur Ventures","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Zileuton","moa":"5-LOX","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Novateur Ventures","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Controlled Release Formulation","sponsorNew":"Novateur Ventures \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Novateur Ventures \/ Not Applicable"},{"orgOrder":0,"company":"IntelGenx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Montelukast Sodium","moa":"CysLT1","graph1":"Neurology","graph2":"Phase II","graph3":"IntelGenx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"buccal film","sponsorNew":"IntelGenx \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"IntelGenx \/ Not Applicable"},{"orgOrder":0,"company":"IntelGenx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Montelukast Sodium","moa":"CysLT1","graph1":"Neurology","graph2":"Phase II","graph3":"IntelGenx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Buccal Film","sponsorNew":"IntelGenx \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"IntelGenx \/ Not Applicable"},{"orgOrder":0,"company":"IntelGenx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Montelukast Sodium","moa":"CysLT1","graph1":"Neurology","graph2":"Phase II","graph3":"IntelGenx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Buccal Film","sponsorNew":"IntelGenx \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"IntelGenx \/ Not Applicable"},{"orgOrder":0,"company":"IntelGenx","sponsor":"Karolinska Institute","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Collaboration","leadProduct":"Montelukast Sodium","moa":"","graph1":"Neurology","graph2":"Phase II","graph3":"IntelGenx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Film","sponsorNew":"IntelGenx \/ Karolinska Institute","highestDevelopmentStatusID":"8","companyTruncated":"IntelGenx \/ Karolinska Institute"},{"orgOrder":0,"company":"IntelGenx","sponsor":"Karolinska University Hospital","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Agreement","leadProduct":"Montelukast Sodium","moa":"","graph1":"Neurology","graph2":"Phase II","graph3":"IntelGenx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Film","sponsorNew":"IntelGenx \/ Karolinska University Hospital","highestDevelopmentStatusID":"8","companyTruncated":"IntelGenx \/ Karolinska University Hospital"},{"orgOrder":0,"company":"IntelGenx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Montelukast Sodium","moa":"","graph1":"Neurology","graph2":"Phase II","graph3":"IntelGenx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Film","sponsorNew":"IntelGenx \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"IntelGenx \/ Not Applicable"},{"orgOrder":0,"company":"IntelGenx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Montelukast Sodium","moa":"","graph1":"Neurology","graph2":"Phase II","graph3":"IntelGenx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Film","sponsorNew":"IntelGenx \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"IntelGenx \/ Not Applicable"},{"orgOrder":0,"company":"IntelGenx","sponsor":"Tilray","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Montelukast Sodium","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"IntelGenx","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Film","sponsorNew":"IntelGenx \/ Tilray","highestDevelopmentStatusID":"12","companyTruncated":"IntelGenx \/ Tilray"},{"orgOrder":0,"company":"IntelGenx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Montelukast Sodium","moa":"","graph1":"Neurology","graph2":"Phase II","graph3":"IntelGenx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Film","sponsorNew":"IntelGenx \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"IntelGenx \/ Not Applicable"},{"orgOrder":0,"company":"IntelGenx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Montelukast Sodium","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"IntelGenx","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"IntelGenx \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"IntelGenx \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Montelukast Sodium

    Menu

    Montelukast Sodium

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    ANALYTICAL

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            IntelGenx

                            Canada arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            IntelGenx

                            Canada arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Montelukast Sodium

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            IntelGenx Reports Preliminary Results for Montelukast VersaFilm® in Alzheimer’s Disease

                            Details : Montelukast VersaFilm (montelukast) is a small molecule CysLT1 receptor inhibitor, given in the form of buccal film, is currently being ivestigated for patients with alzheimer's disease.

                            Brand Name : Montelukast VersaFilm

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            July 03, 2024

                            Lead Product(s) : Montelukast Sodium

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            IntelGenx

                            Canada arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            IntelGenx

                            Canada arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Montelukast Sodium

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            IntelGenx Doses First Parkinson’s Patients with Montelukast VersaFilm in Phase 2 Trial

                            Details : Montelukast VersaFilm (montelukast) is a leukotriene receptor antagonist, which is being evaluated in patients with Parkinson’s Disease, the second most common neurodegenerative disease.

                            Brand Name : Montelukast VersaFilm

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            April 08, 2024

                            Lead Product(s) : Montelukast Sodium

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            IntelGenx

                            Canada arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            IntelGenx

                            Canada arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Montelukast Sodium

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            IntelGenx Receives Approval to Conduct MONTPARK™ Montelukast VersaFilm® Phase 2 Clinical Trial in Patients ...

                            Details : VersaFilm® (montelukast) is a leukotriene receptor antagonist, which is completed patient enrollment in the ongoing Phase 2a clinical trial in patients with mild to moderate Alzheimer’s Disease.

                            Brand Name : Montelukast VersaFilm

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            November 14, 2023

                            Lead Product(s) : Montelukast Sodium

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            IntelGenx

                            Canada arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            IntelGenx

                            Canada arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Montelukast Sodium

                            Therapeutic Area : Neurology

                            Study Phase : Approved

                            Sponsor : Tilray

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            IntelGenx Announces Co-development and Commercialization of Cannabinoid-Infused VersaFilm® Products with Tilr...

                            Details : The agreement aims for the co-development and commercialization of cannabinoid-infused VersaFilm® products, including CBD VersaFilm (cannabinoid), a unique drug opportunity for the treatment of neurodegenerative diseases of the brain.

                            Brand Name : CBD VersaFilm

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            November 06, 2023

                            Lead Product(s) : Montelukast Sodium

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved

                            Sponsor : Tilray

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            IntelGenx

                            Canada arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            IntelGenx

                            Canada arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Montelukast Sodium

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            IntelGenx Completes Enrollment for ‘BUENA’ Montelukast VersaFilm® Phase 2a Clinical Trial in Patients wit...

                            Details : VersaFilm® (montelukast) is a leukotriene receptor antagonist, which is completed patient enrollment in the ongoing Phase 2a clinical trial in patients with mild to moderate Alzheimer’s Disease.

                            Brand Name : Montelukast VersaFilm

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            August 01, 2023

                            Lead Product(s) : Montelukast Sodium

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            IntelGenx

                            Canada arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            IntelGenx

                            Canada arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Montelukast Sodium

                            Therapeutic Area : Neurology

                            Study Phase : IND Enabling

                            Sponsor : Karolinska University Hospital

                            Deal Size : $2.0 million

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            IntelGenx Provides Update on Research Collaboration Evaluating Montelukast VersaFilm® for the Treatment of Pa...

                            Details : The agreement aims to investigate the use of IntelGenx’s Montelukast VersaFilm, a leukotriene receptor antagonist, for the treatment of Parkinson’s Disease.

                            Brand Name : Montelukast VersaFilm

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            July 25, 2023

                            Lead Product(s) : Montelukast Sodium

                            Therapeutic Area : Neurology

                            Highest Development Status : IND Enabling

                            Sponsor : Karolinska University Hospital

                            Deal Size : $2.0 million

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            IntelGenx

                            Canada arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            IntelGenx

                            Canada arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Montelukast Sodium

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : Karolinska Institute

                            Deal Size : $2.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            IntelGenx Announces Research Collaboration with Renowned Neurologist to Evaluate Montelukast VersaFilm for the...

                            Details : Upon completion of the Study, IntelGenx will retain the intellectual property rights and use the findings to further develop its Montelukast VersaFilm® program for Parkinson's disease treatment.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            February 09, 2023

                            Lead Product(s) : Montelukast Sodium

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : Karolinska Institute

                            Deal Size : $2.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            IntelGenx

                            Canada arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            IntelGenx

                            Canada arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Montelukast Sodium

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            First Patient Dosed in IntelGenx’s Resumed ‘BUENA’ Montelukast VersaFilm® Phase 2a Clinical Trial in Pa...

                            Details : Resumption of patient dosing in the ongoing Phase 2a (BUENA) clinical trial of Montelukast VersaFilm, a leukotriene receptor antagonist on the basis of Phase 1 study data that reduces the first-pass-effect and has a 52% higher bioavailability.

                            Brand Name : Montelukast-Generic

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            January 20, 2022

                            Lead Product(s) : Montelukast Sodium

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            IntelGenx

                            Canada arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            IntelGenx

                            Canada arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Montelukast Sodium

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Patient Screening to Resume in IntelGenx’s ‘BUENA’ Montelukast VersaFilm® Phase 2a Clinical Trial in Pa...

                            Details : In Phase 1 studies, an oral film formulation of Montelukast is safe and tolerable in healthy subjects, reduces the first-pass-effect and has a 52% higher bioavailability compared to the Montelukast tablet, demonstrating a clear advantage of delivering Mo...

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            October 12, 2021

                            Lead Product(s) : Montelukast Sodium

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            IntelGenx

                            Canada arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            IntelGenx

                            Canada arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Montelukast Sodium

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            IntelGenx Announces Publication of a Study Evaluating Montelukast’s Effect on Neurological Aging

                            Details : Data suggest Montelukast may inhibit mental decline, higher doses optimal for clinical trials assessing impact on neurological disease.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            November 09, 2020

                            Lead Product(s) : Montelukast Sodium

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth